相关实验视频
Updated: Jan 15, 2026

03:52
The Creation of a Rat Model for Osteosarcopenia via Ovariectomy
Published on: February 21, 2025
1.1K
阿托瓦斯塔丁与肉症之间的关联:基于NHANES和FAERS数据库的研究
Hao Zhang1, Ping Zhang1, Xi Luo1
1Department of Pharmacy, Chengdu Seventh People's Hospital (Affiliated Cancer Hospital of Chengdu Medical College), No. 1188 Shuangxing Avenue, Shuangliu District, Chengdu, 610213, Sichuan, China.
Naunyn-Schmiedeberg's archives of pharmacology
|October 8, 2025
概括
使用阿托尔瓦斯塔丁可能会增加患肉症的风险,这是一种肌肉消耗的疾病. 这项研究分析了健康数据,发现了显著的关联,并建议长期使用他类药物治疗的患者定期进行肌肉评估.
科学领域:
- 药物监督 药物监督 药物监督
- 流行病学 流行病学
- 老年学是指老年学的学科.
背景情况:
- 市场推广后的监测表明,阿托瓦斯塔丁与肉症之间存在潜在的联系.
- 需要进行大规模的观测研究来证实这一关联.
- 了解这种关系对于优化阿托瓦斯塔丁的安全性和疗效概况至关重要.
研究的目的:
- 综合调查阿托瓦斯塔丁暴露与肉类的关系.
- 为临床指导提供准确的安全性和疗效数据.
- 评估与阿托瓦斯塔丁使用相关的肉类的风险.
主要方法:
- 使用了国家健康和营养检查调查 (NHANES) 数据 (2011-2018) 和食品和药物管理局不良事件报告系统 (FAERS) 数据 (2004-2018).
- 采用描述性统计,多变量后勤回归和接收器操作特征 (ROC) 曲线分析.
- 进行了基于人口的流行病学调查和药监系统分析.
主要成果:
- 在NHANES的多变量逻辑回归表明,阿托瓦斯塔丁的使用与增加的肉症风险有关 (OR=2.21;95% CI:1.07-4.55;p=0.032).
- 在FAERS分析中,在13,625份阿托瓦斯塔丁不良事件报告中,发现了5370起与髓相关的事件.
- 两个数据集的独立分析始终表明,在使用阿托瓦斯塔丁时,沙丘的风险可能会增加.
结论:
- 阿托尔瓦斯塔丁的使用可能与沙科佩尼亚的风险增加有关.
- 医疗保健提供者应告知这些风险,并考虑对长期接受阿托瓦斯塔丁治疗的患者进行定期肌肉骨评估.
- 这些研究结果支持在他类药物治疗中需要全面的风险管理策略.
相关概念视频
Drug Dosing: Obese Patients
222
In the United States, obesity is a prominent concern. It is linked to heightened mortality rates due to increased occurrences of conditions such as hypertension, atherosclerosis, coronary artery disease, and diabetes compared to nonobese individuals. A patient is classified as obese if their actual body weight surpasses the ideal or desirable body weight by 20%, based on Metropolitan Life Insurance Company data. Ideal body weights consider average weights and heights for males and females...
222
Pharmacokinetics in Obese Patients: Drug Absorption and Distribution
246
Obesity significantly alters the pharmacokinetic processes of drug absorption and distribution, presenting unique challenges in medical treatment. The increased fat tissue and decreased lean muscle in obese individuals can significantly affect how drugs are absorbed into the body and distributed across different tissues. This alteration can lead to variances in the effectiveness and safety of medications, necessitating adjustments in dosing or drug selection for obese patients.One notable...
246
Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion
166
Drug metabolism, a critical process in the liver, involves two primary phases: Phase I reactions and Phase II conjugation. Obesity introduces significant alterations in this metabolic process, primarily due to fatty infiltration of the liver, leading to conditions such as nonalcoholic fatty liver disease (NAFLD). This condition can modify the activities of both Phase I and II enzymes, impacting how drugs are metabolized in obese patients.Phase I metabolism sees variable effects across...
166
Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Metabolism
196
Geriatric patients show significant variation in how their bodies process medications, which can change how effective and safe treatments are. The liver is the primary organ where drug metabolism occurs, involving two main types of chemical reactions: phase I and II. Phase I metabolism is driven by the cytochrome P450 enzyme system, which includes key types such as CYP3A, CYP2D6, and CYP2C9. Research indicates that while aging doesn't notably alter the levels or activity of these enzymes, it...
196
Obesity
1.1K
The Body Mass Index (BMI) is a numerical value derived from a person's weight and height, used to categorize individuals into weight ranges. It is calculated using the formula: weight in kilograms divided by height in meters squared. Obesity is a health condition characterized by excessive accumulation of adipose tissue that poses health risks, often diagnosed with a BMI ≥ 30. This excess fat storage occurs when surplus dietary calories are converted into triglycerides and stored in...
1.1K
Changes in the Appendicular Skeleton with Age
3.4K
The upper and lower limb initially develops as a small bulge called a limb bud, which appears on the lateral side of the early embryo. The upper limb bud appears near the end of the fourth week of development, with the lower limb bud appearing shortly after.
Initially, the limb buds consist of a core of mesenchyme covered by a layer of ectoderm. The ectoderm at the end of the limb bud thickens to form a narrow crest called the apical ectodermal ridge. This ridge stimulates the underlying...
Initially, the limb buds consist of a core of mesenchyme covered by a layer of ectoderm. The ectoderm at the end of the limb bud thickens to form a narrow crest called the apical ectodermal ridge. This ridge stimulates the underlying...
3.4K

